SMARCA4 mutations, reported as the most frequent mutations in the SWI/SNF complex, are associated with poor prognosis in lung cancer, although SMARCA4-mutated lung cancer may be more sensitive to immunotherapy (24). This evidence concerns the gene SMARCA4 and lung cancer.